{"schema_version":"1.0","type":"article","title":"特發性肺纖維化 迎來爆發","url":"https://drugnews.com.tw/articles/2026-04-12-dcard-261282303.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-12-dcard-261282303.md","lang":"zh-Hant","date":"2026-04-12","publish_at":"2026-04-12T10:30:00+08:00","updated_at":"2026-04-12","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","自體免疫","臨床數據","生技投資"],"summary":"特發性肺纖維化，idiopathic pulmonary fibrosis（IPF），從來都不是一個容易講出樂觀故事的領域。這是一種慢性、進行性、不可逆的纖維化肺病，預後差、死亡風險高，過去長年幾乎等同於「只能拖慢，不能扭轉」。","key_points":[],"facts":[],"sections":["IPF 真的要熱起來了：雙寡頭鬆動之後，下一輪肺纖維化大戰已經開打","雙寡頭鬆動的起點","2026 年第一梯隊：最接近商業化拐點的玩家","第二梯隊：下一輪賽局參與者已經排隊進場","更後排的觀察名單：第二波卡位戰也已經開始","真正要開打的，不只是數據，而是新標準治療的位置"],"references":[{"title":"[0]:各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"Youtube","source":"","date":"","url":""},{"title":"Idiopathic pulmonary fibrosis (IPF) is a progressive lung disorder characterized by scarring of the lungs from an unknown cause. The condition has a poor long-term prognosis. Classical features of IPF include the gradual onset of shortness of breath, prog","source":"","date":"","url":""},{"title":"www.ncbi.nlm.nih.gov","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"Sandoz launches first generic pirfenidone in US","source":"Sandoz US","date":"","url":""},{"title":"Pirfenidone is used to treat idiopathic pulmonary fibrosis (IPF),1 a progressive disease that causes irreversible lung scarring and makes it difficult to breathe2 Approximately 140,000 Americans live with IPF, a rare disease with no cure, and 50,000 new c","source":"","date":"","url":""},{"title":"www.sandoz.com","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine – United Therapeutics Investor Relations","source":"","date":"","url":""},{"title":"The actual press release articles","source":"","date":"","url":""},{"title":"ir.unither.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"www.bms.com","source":"","date":"","url":""},{"title":"https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMS-JPM-2026-Presentation.pdf?utm_source=chatgpt.com","source":"","date":"","url":"https://www.bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMS-JPM-2026-Presentation.pdf?utm_source=chatgpt.com"},{"title":"www.bms.com","source":"","date":"","url":""},{"title":"\"BMS-JPM-2026-Presentation.pdf\"","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"Endeavor BioMedicines Receives Priority Medicines (PRIME) Designation from the European Medicines Agency for Taladegib (ENV-101) for the Treatment of Idiopathic Pulmonary Fibrosis","source":"Endeavor BioMedicines","date":"","url":""},{"title":"https://endeavorbiomedicines.com/endeavor-biomedicines-receives-priority-medicines-prime-designation-from-the-european-medicines-agency-for-taladegib-env-101-for-the-treatment-of-idiopathic-pulmonary-fibrosis/","source":"","date":"","url":"https://endeavorbiomedicines.com/endeavor-biomedicines-receives-priority-medicines-prime-designation-from-the-european-medicines-agency-for-taladegib-env-101-for-the-treatment-of-idiopathic-pulmonary-fibrosis/"},{"title":"endeavorbiomedicines.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：特發性肺纖維化 迎來爆發（圖 1）","url":"https://drugnews.com.tw/assets/articles/dcard-261282303/dcard-01.webp"},{"alt":"Dcard 原圖：特發性肺纖維化 迎來爆發（圖 2）","url":"https://drugnews.com.tw/assets/articles/dcard-261282303/dcard-02.webp"},{"alt":"Dcard 原圖：特發性肺纖維化 迎來爆發（圖 3）","url":"https://drugnews.com.tw/assets/articles/dcard-261282303/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/dcard-261282303/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-12）。特發性肺纖維化 迎來爆發。https://drugnews.com.tw/articles/2026-04-12-dcard-261282303.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-12-dcard-261282303-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}